Infliximab-associated focal segmental glomerulosclerosis in a patient with ankylosing spondylitis

Abstract

The introduction of tumor necrosis factor-alpha (TNF-α)-targeting drugs has given new opportunities in the treatment of various inflammatory rheumatic diseases and has been the most important development in the treatment of spondyloarthritis (SpA). However, the increasing use and longer follow-up periods of treatment also pose risks of developing various adverse effects ranging from common ones including infections to uncommon renal complications. This report describes a case of infliximab-induced focal segmental glomerulosclerosis (FSGS) in a 40-year-old female patient with ankylosing spondylitis (AS) who presented with asymptomatic proteinuria and microscopic hematuria. To the best of our knowledge, this is the second reported case of FSGS attributed to infliximab (IFX). A review of the English literature was conducted for cases of possible IFX-associated renal disorders in patients with SpA and SpA spectrum diseases. In this respect, the reported renal pathologies were IgA nephropathy, crescentic glomerulonephritis, acute renal artery occlusion, acute tubulointerstitial nephritis (ATIN), FSGS, and membranous glomerulopathy. Furthermore, partial or complete resolution was reported after cessation of therapy. In conclusion, although renal complications of TNF inhibitors (TNFi) are uncommon, spot urine evaluation may be recommended in the follow-up of patients treated with TNFi.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. 1.

    Samson M, Espigol-Frigole G, Terrades-Garcia N, Prieto-Gonzalez S, Corbera-Bellalta M, Alba-Rovira R, Hernandez-Rodriguez J, Audia S, Bonnotte B, Cid MC (2018) Biological treatments in giant cell arteritis & Takayasu arteritis. Eur J Intern Med 50:12–19. https://doi.org/10.1016/j.ejim.2017.11.003

    Article  PubMed  Google Scholar 

  2. 2.

    Ramos-Casals M, Brito-Zeron P, Munoz S, Soto MJ, Group BS (2008) A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 87(6):345–364. https://doi.org/10.1097/MD.0b013e318190f170

    Article  Google Scholar 

  3. 3.

    Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA (2008) Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22(5):847–861. https://doi.org/10.1016/j.berh.2008.09.008

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Lee SH, Lee EJ, Chung SW, Song R, Moon JY, Lee SH, Lim SJ, Lee YA, Hong SJ, Yang HI (2013) Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker. Rheumatol Int 33(7):1689–1692. https://doi.org/10.1007/s00296-012-2624-9

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    Strobel ES, Fritschka E (1998) Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol 17(6):524–530

    Article  CAS  PubMed  Google Scholar 

  6. 6.

    Jones DW, Mansell MA, Samuell CT, Isenberg DA (1987) Renal abnormalities in ankylosing spondylitis. Br J Rheumatol 26(5):341–345

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Leonard D, Cortese C, Wadei HM, Porter Ii IE, Aslam N (2018) Behcet’s syndrome and focal segmental glomerulosclerosis with nephrotic syndrome - successful treatment with etanercept. Clin Nephrol 89(5):371–375. https://doi.org/10.5414/CN109262

    Article  CAS  PubMed  Google Scholar 

  8. 8.

    Dumitrescu G, Dahan K, Treton X, Corcos O, Bouhnik Y, Stefanescu C (2015) Nephrotic syndrome after infliximab treatment in a patient with ulcerative colitis. J Gastrointestin Liver Dis 24(2):249–251. https://doi.org/10.15403/jgld.2014.1121.242.infx

    Article  PubMed  Google Scholar 

  9. 9.

    Jacquet A, Francois H, Frangie C, Yahiaoui Y, Ferlicot S, Micelli C, Mariette X, Durrbach A (2009) IgA nephropathy associated with ankylosing spondylitis is not controlled by infliximab therapy. Nephrol Dial Transplant 24(11):3540–3542. https://doi.org/10.1093/ndt/gfp314

    Article  CAS  PubMed  Google Scholar 

  10. 10.

    Hatakeyama T, Komatsuda A, Matsuda A, Togashi M, Maki N, Masai R, Sawada K, Wakui H (2008) Renal amyloidosis associated with extracapillary glomerulonephritis and vasculitis in a patient with inflammatory bowel disease treated with infliximab. Clin Nephrol 70(3):240–244

    Article  CAS  PubMed  Google Scholar 

  11. 11.

    Lemaitre C, Iwanicki-Caron I, Vecchi CD, Bertiaux-Vandaele N, Savoye G (2013) Acute renal artery occlusion following infliximab infusion. World J Nephrol 2(3):90–93. https://doi.org/10.5527/wjn.v2.i3.90

    Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Ota M, Iwai H, Imai K, Kamiya M, Yoshihashi-Nakazato Y, Miyasaka N, Kohsaka H (2016) Acute Tubulointerstitial Nephritis Associated with Infliximab in a Patient with Crohn’s Disease. Intern Med 55(10):1367–1370. https://doi.org/10.2169/internalmedicine.55.5834

    Article  CAS  PubMed  Google Scholar 

  13. 13.

    Yoo YJ, Chung SY, Gu DH, Ko GJ, Pyo HJ, Kwon YJ, Bak YT, Won NH (2014) A case of late onset-acute tubulointerstitial nephritis with infliximab and mesalazine treatment in a patient with Crohn’s disease. Korean J Gastroenterol 63(5):308–312

    Article  PubMed  Google Scholar 

  14. 14.

    Chin G, Luxton G, Harvey JM (2005) Infliximab and nephrotic syndrome. Nephrol Dial Transplant 20(12):2824–2826. https://doi.org/10.1093/ndt/gfi180

    Article  CAS  PubMed  Google Scholar 

  15. 15.

    Sato T, Kawasaki Y, Ito A, Izumi H, Kawamorita N, Yamashita S, Mitsuzuka K, Matsuura T, Watanabe M, Arai Y (2018) Infliximab-Induced Tubulointerstitial Nephritis with Image Findings of Striated Nephrogram in Crohn’s Disease. Tohoku J Exp Med 245(3):149–152. https://doi.org/10.1620/tjem.245.149

    Article  PubMed  Google Scholar 

  16. 16.

    Piga M, Chessa E, Ibba V, Mura V, Floris A, Cauli A, Mathieu A (2014) Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun Rev 13(8):873–879. https://doi.org/10.1016/j.autrev.2014.05.005

    Article  CAS  PubMed  Google Scholar 

  17. 17.

    Kluger N, Du-Thanh A, Bessis D, Servel MF, Mourad G (2015) Psoriasis-associated IgA nephropathy under infliximab therapy. Int J Dermatol 54(3):e79–e80. https://doi.org/10.1111/ijd.12622

    Article  CAS  PubMed  Google Scholar 

  18. 18.

    Ueno Y, Tanaka S, Onitake T, Hanaoka R, Yoshioka K, Ito M, Chayama K (2009) Infliximab treatment for Crohn’s disease in a patient with IgA nephropathy. Clin J Gastroenterol 2(6):380–383. https://doi.org/10.1007/s12328-009-0112-x

    Article  PubMed  Google Scholar 

  19. 19.

    Prinz JC (2011) Autoimmune-like syndromes during TNF blockade: does infection have a role? Nat Rev Rheumatol 7(7):429–434. https://doi.org/10.1038/nrrheum.2011.35

    Article  CAS  PubMed  Google Scholar 

  20. 20.

    McCarthy ET, Sharma M (2002) Indomethacin protects permeability barrier from focal segmental glomerulosclerosis serum. Kidney Int 61(2):534–541. https://doi.org/10.1046/j.1523-1755.2002.00172.x

    Article  CAS  PubMed  Google Scholar 

  21. 21.

    Laurent J, Belghiti D, Bruneau C, Lagrue G (1987) Diclofenac, a nonsteroidal anti-inflammatory drug, decreases proteinuria in some glomerular diseases: a controlled study. Am J Nephrol 7(3):198–202. https://doi.org/10.1159/000167463

    Article  CAS  PubMed  Google Scholar 

  22. 22.

    Vogt L, Laverman GD, Navis G (2010) Time for a comeback of NSAIDs in proteinuric chronic kidney disease? Neth J Med 68(12):400–407

    CAS  PubMed  Google Scholar 

  23. 23.

    de Borst MH, Nauta FL, Vogt L, Laverman GD, Gansevoort RT, Navis G (2012) Indomethacin reduces glomerular and tubular damage markers but not renal inflammation in chronic kidney disease patients: a post-hoc analysis. PLoS One 7(5):e37957. https://doi.org/10.1371/journal.pone.0037957

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

There is no source(s) of support in the form of grants or industrial support.

Author information

Affiliations

Authors

Contributions

All the authorship contributions were declared in line with the ICMJE 4 criteria: Dr. Yarkan Tuğsal and Dr. Birlik wrote the paper. Dr. Zengin and Dr. Kenar searched the databases for review of the literature. Dr. Can and Dr. Önen read the selected articles and evaluated for eligibility. Dr. Ünlü evaluated pathology of the kidney. Dr. Yarkan Tuğsal, Dr. Kenar and Dr. Birlik revised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Corresponding author

Correspondence to Handan Yarkan Tuğsal.

Ethics declarations

Conflict of interest

All the authors declare that they have no conflicts of interest.

Informed consent

The patient gave a written informed consent before written.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yarkan Tuğsal, H., Zengin, B., Kenar, G. et al. Infliximab-associated focal segmental glomerulosclerosis in a patient with ankylosing spondylitis. Rheumatol Int 39, 561–567 (2019). https://doi.org/10.1007/s00296-019-04241-8

Download citation

Keywords

  • Infliximab
  • Focal segmental glomerulosclerosis
  • Ankylosing spondylitis